Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selenium nanoparticle capsules plus omalizumab in chronic spontaneous urticaria
ChiCTR2600121306Phase 4Recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of omalizumab and selenium nanoparticle capsules in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Mean number of days of antihistamine use per week at Month 4. Started Mar 2026; status: recruiting.
02
Drugs
omalizumabselenium nanoparticle capsules
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on ChiCTR2600121306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121306.